美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kalaris Therapeutics Inc.

10.77

+0.77007.70%

盤後：10.770.00000.00%16:10 EST

成交量：10.39萬

成交額：108.61萬

市值：2.01億

市盈率：-3.11

高：11.02

開：10.50

低：9.81

收：10.00

52周最高：12.90

52周最低：2.14

股本：1,870.24萬

流通股本：430.93萬

量比：0.99

換手率：2.41%

股息：- -

股息率：- -

每股收益(TTM):-3.4594

每股收益(LYR):-10.4377

淨資產收益率：--

總資產收益率：-63.50%

市淨率：4.81

市盈率(LYR):-1.03

資料載入中...

總覽公司新聞資訊公告

Kalaris Therapeutics, Inc.盤中異動臨近午盤股價大跌6.35%

Kalaris Therapeutics公布TH103在未接受治療的血管新生性AMD中初步1a期數據積極

Kalaris Therapeutics：第一階段單次遞增劑量試驗預計年底前將披露初步臨床數據

新聞稿：Kalaris擴展領導團隊，任命Matthew Gall為首席財務官

Kalaris Therapeutics正在招募TH103治療新生血管性年齡相關性黃斑變性的1B/2期多劑量遞增研究

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KLRS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":10.77,"timestamp":1771880400000,"preClose":10,"halted":0,"volume":103919,"hourTrading":{"tag":"盘后","latestPrice":10.77,"preClose":10.77,"latestTime":"16:10 EST","volume":318,"amount":3424.8599999999997,"timestamp":1771881004674,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07699999999999996,"floatShares":4309313,"shares":18702418,"eps":-3.459444,"marketStatus":"盤後交易","change":0.77,"latestTime":"02-23 16:45:54 EST","open":10.5,"high":11.02,"low":9.81,"amount":1086057.6815,"amplitude":0.121,"askPrice":11.92,"askSize":100,"bidPrice":7.31,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.459444,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":10,"preHourTrading":{"tag":"盘前","latestPrice":10.2,"preClose":10,"latestTime":"09:17 EST","volume":71,"amount":713.799991,"timestamp":1771856241591,"change":0.2,"changeRate":0.02,"amplitude":0.02},"postHourTrading":{"tag":"盘后","latestPrice":10.77,"preClose":10.77,"latestTime":"16:10 EST","volume":318,"amount":3424.8599999999997,"timestamp":1771881004674,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.994398},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":4309313,"roa":"-63.50%","roe":"--","lyrEps":-10.437743,"volumeRatio":0.994398,"shares":18702418,"dividePrice":0,"high":11.02,"amplitude":0.121,"preClose":10,"low":9.81,"week52Low":2.14,"pbRate":"4.81","week52High":12.9,"institutionHeld":0,"latestPrice":10.77,"eps":-3.459444,"divideRate":0,"volume":103919,"delay":0,"ttmEps":-3.459444,"open":10.5,"prevYearClose":8.44,"prevWeekClose":10,"prevMonthClose":8.88,"prevQuarterClose":8.44,"fiveDayClose":8.65,"twentyDayClose":9.8,"sixtyDayClose":6.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"KLRS","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.64},{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61},{"market":"US","date":"2025-05-14","symbol":"KLRS","fiscalQuarterEnding":"2025/03","expectedEps":-0.78,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-2.52},{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-01-16","symbol":"KLRS","defaultRemindTime":1737037800000,"type":"split","dateTimestamp":1737003600000,"forFactor":23,"toFactor":1,"ratio":23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.3333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1766552400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2026-02-20","current":-3.114662,"percent":0,"low":-3.702314,"twenty":-2.785165,"median":-1.136034,"eighty":-0.665305,"high":-0.558935,"avg":-1.571968,"sd":0.934602,"marketCap":205352549},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143},{"date":"2025-10-10","current":-1.059306,"twenty":-1.715927,"median":-0.815379,"eighty":-0.632803,"marketCap":86498683},{"date":"2025-10-17","current":-1.097097,"twenty":-1.652483,"median":-0.853303,"eighty":-0.634281,"marketCap":89584582},{"date":"2025-10-24","current":-1.120001,"twenty":-1.598641,"median":-0.878784,"eighty":-0.635266,"marketCap":91454824},{"date":"2025-10-31","current":-1.085645,"twenty":-1.578566,"median":-0.913935,"eighty":-0.635266,"marketCap":88649461},{"date":"2025-11-07","current":-1.083355,"twenty":-1.543053,"median":-0.93448,"eighty":-0.63822,"marketCap":88462437},{"date":"2025-11-14","current":-1.220778,"twenty":-1.513949,"median":-0.991739,"eighty":-0.641667,"marketCap":99683887},{"date":"2025-11-21","current":-2.326591,"twenty":-1.652483,"median":-1.007772,"eighty":-0.642652,"marketCap":129046684},{"date":"2025-11-28","current":-2.104047,"twenty":-1.7661,"median":-1.019224,"eighty":-0.643637,"marketCap":116703088},{"date":"2025-12-05","current":-1.996147,"twenty":-1.811647,"median":-1.04043,"eighty":-0.647085,"marketCap":110718314},{"date":"2025-12-12","current":-2.808768,"twenty":-1.83375,"median":-1.046709,"eighty":-0.650039,"marketCap":155791141},{"date":"2025-12-19","current":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"marketCap":194879195},{"date":"2025-12-26","current":-3.230252,"twenty":-1.885652,"median":-1.065031,"eighty":-0.655456,"marketCap":179169164},{"date":"2026-01-02","current":-2.845859,"twenty":-1.914397,"median":-1.075338,"eighty":-0.657426,"marketCap":157848407},{"date":"2026-01-09","current":-2.785165,"twenty":-1.996147,"median":-1.083355,"eighty":-0.657426,"marketCap":154481972},{"date":"2026-01-16","current":-2.987477,"twenty":-2.104047,"median":-1.089081,"eighty":-0.657426,"marketCap":165703423},{"date":"2026-01-23","current":-3.29769,"twenty":-2.164782,"median":-1.092517,"eighty":-0.659396,"marketCap":182909648},{"date":"2026-01-30","current":-3.102121,"twenty":-2.196152,"median":-1.097097,"eighty":-0.661858,"marketCap":172062245},{"date":"2026-02-06","current":-2.815512,"twenty":-2.367922,"median":-1.114275,"eighty":-0.662351,"marketCap":156165190},{"date":"2026-02-13","current":-3.02794,"twenty":-2.502772,"median":-1.122292,"eighty":-0.662351,"marketCap":167947713},{"date":"2026-02-20","current":-3.702314,"twenty":-2.785165,"median":-1.136034,"eighty":-0.665305,"marketCap":205352549}],"updateTime":1771876841121},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609314240","title":"Kalaris Therapeutics, Inc.盤中異動 臨近午盤股價大跌6.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609314240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609314240?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 00:55","pubTimestamp":1770224103,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日00时55分，Kalaris Therapeutics, Inc.股票出现波动，股价快速跳水6.35%。Kalaris Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。其相关个股中，Liminatus Pharma, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Gri Bio, Inc.、Evogene Ltd.较为活跃，换手率分别为412.60%、208.91%、134.82%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Liminatus Pharma, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为61.25%、44.85%、35.12%。Kalaris Therapeutics, Inc.公司简介：Kalaris Therapeutics Inc是一家临床阶段的生物制药公司，专注于开发和商业化流行视网膜疾病的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205005503953fd998&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205005503953fd998&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KLRS","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"1142712562","title":"Kalaris Therapeutics公布TH103在未接受治療的血管新生性AMD中初步1a期數據積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1142712562","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142712562?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 05:03","pubTimestamp":1766005389,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics公布TH103在未接受治疗的血管新生性AMD中初步1a期数据积极","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"1117531396","title":"Kalaris Therapeutics：第一階段單次遞增劑量試驗預計年底前將披露初步臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1117531396","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117531396?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 21:08","pubTimestamp":1762952910,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics：第一阶段单次递增剂量试验预计年底前将披露初步临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"1158357876","title":"新聞稿：Kalaris擴展領導團隊，任命Matthew Gall為首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=1158357876","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158357876?lang=zh_tw&edition=fundamental","pubTime":"2025-11-03 20:34","pubTimestamp":1762173260,"startTime":"0","endTime":"0","summary":"首席财务官的任命增强了Kalaris的领导团队，以支持公司在治疗未接受治疗的nAMD患者的1b/2期研究中的持续增长。加利福尼亚州帕洛阿尔托，2025年11月3日—— Kalaris Therapeutics，一家致力于开发和商业化常见视网膜疾病治疗的临床阶段生物制药公司，今天宣布任命Matthew Gall，MBA为首席财务官。Matthew Gall表示：“在公司重要的发展时刻，我很高兴加入Kalaris Therapeutics的领导团队。我期待能够帮助Kalaris实现其改变视网膜疾病患者治疗格局的使命。”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS","BK4120","TISI"],"gpt_icon":0},{"id":"1104736870","title":"Kalaris Therapeutics正在招募TH103治療新生血管性年齡相關性黃斑變性的1B/2期多劑量遞增研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1104736870","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104736870?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:04","pubTimestamp":1757937876,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics目前正在招募TH103用于治疗新生血管性年龄相关性黄斑变性的1B/2期多剂量递增研究患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}